Objective: To assess the effect of Xinmaitong (XMT) capsule in treating coronaryheart disease (CHD). Methods: Thirty-eightpatients of coronary heart disease with myocardial ischemia were divided randomly intoXMT group (20 cases) and control group (18cases). Conventional western medical therapywas given to both groups and the XMT groupreceived additional XMT treatment. Thechanges of endothelin (ET ) and calcitoningene-related peptide (CGRP) levels, ST segment of ECG and clinical symptoms aftertreatment in all the patients were observed.Data of 14 healthy persons were taken as normal control. Results: The ET level of all patients was significantly higher than that of thenormal control (P < 0. 001 ), and level ofCGRP in patients was not different from normal control significantly (P > 0. 05 ). Aftertreatment, results showed that: (1 ) The ETlevels and the scores of clinical symptoms ofboth groups decreased significantly (P <0. 01 ), and ST segment elevated markedly(P< 0. 01) as compared with before treatment, and the changes revealed more evidentin XMT group in comparison with those of thecontrol group (P < 0.05 - 0.01 ). (2 ) Thelevel of CGRP was significantly increased inXMT group (P < 0. 01 ) while unchanged inthe control group (P > 0. 05 ). Conclusions:There is severe damage of vascular endothelialcells in CHD patients. XMT could not only reduce significantly the plasma ET content, butalso enhance markedly the production and release of CGRP, so it has a good anti--ischemiceffect, which may be closely related with itsaction on improving the function of vascularendothelial cells and regulating metabolism ofET and CGRP. Objective: To assess the effect of Xinmaitong (XMT) capsule in the treatment of coronary heart disease (CHD). Methods: Thirty-eight patients of coronary heart disease with compatible myocardial ischemia were divided randomly into XMT group (20 cases) and control group (18cases). Medical therapywas given to both groups and the XMT groupreceived additional XMT treatment. Thechanges of endothelin (ET ) and calcitoningene-related peptide (CGRP) levels, ST segment of ECG and clinical symptoms aftertreatment in all the patients were observed.Data of 14 healthy persons Were taken as normal control. Results: The ET level of all patients was significantly higher than that of thenormal control (P < 0. 001 ), and level ofCGRP in patients was not different from normal control significantly (P > 0.05). Aftertreatment, results showed that: (1) The ETlevels and the scores of clinical symptoms ofboth networks decreased significantly (P <0. 01 ), and ST segment extended markedly (P< 0. 01) as relative w Ith before treatment, and the changes revealed more evidentinx XMT group in comparison with those of thecontrol group (P < 0.05 - 0.01 ). (2) Thelevel of CGRP was significantly increased inXMT group (P < 0. 01 ) while unchanged in the control group (P > 0.05). Conclusions:There is severe damage of vascular endothelialcells in CHD patients. XMT could not only reduce significantly the plasma ET content, butalso enhance markedly the production and release of CGRP, so it has a good anti-- Ischemic effect, which may be closely related with its action on improving the function of vascularendothelial cells and regulating metabolism ofET and CGRP.